CClinicalTrials.gg
RecruitingNCT05756257BP-VISOUpdated Sep 28, 2026

Blood Pressure Variability and Ischemic Stroke Outcome

An observational study in Acute Ischemic Stroke and Blood Pressure Variability, sponsored by Yale University. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Yale University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are:

  1. To determine the association of BPV with functional/cognitive outcome after ischemic stroke.
  2. To determine a pathophysiologic mechanism of BPV's deleterious effect on functional outcome.
  3. To evaluate potential treatment targets to pharmacologically reduce BPV after ischemic stroke.
Read the detailed description

Increased blood pressure variability (BPV) has consistently been associated with two to three times higher risk of disability or mortality after acute ischemic stroke (AIS) in retrospective analyses, independent of mean blood pressure. The investigators' central hypothesis is that increased BPV is harmful after AIS and warrants reduction. However, prior BPV research in AIS patients has been retrospective and limited by non-standardized BP measurement and, therefore, BPV is not mentioned in current stroke guidelines. To address the limitations of prior BPV research, determine mechanisms of BPV's deleterious effect, and identify potentially effective methods to reduce BPV, the proposed study will: 1) prospectively validate that "short-term" and "long-term" BPV after AIS onset is associated with functional outcome and define the effect size of different levels of BPV, 2) utilize portable MRI to confirm that final infarct volume is mechanistically related to BPV, and 3) utilize bedside pupillometry to determine how the autonomic nervous system contributes to BPV after AIS and evaluate the class effect of antihypertensive medications on BPV. To achieve these goals, the study will enroll 150 patients who have anterior circulation stroke and a baseline NIH Stroke Scale ≥4 within 48 hours of AIS onset at three study sites. With completion of the Aims, the study will define the outcome for a future trial, the effect size of BPV on individual outcomes and composites, the duration for lowering BPV (24-72 hours vs. weeks or months), and potential interventions to reduce BPV. Pharmacologic BPV reduction would be an inexpensive and widely available intervention, able to be administered in a range of healthcare settings. By completing the proposed aims, the investigators will be ideally positioned to test accessible targeted interventions to diminish the morbidity and mortality of AIS.

02

Conditions studied

  • Acute Ischemic Stroke
  • Blood Pressure Variability

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute ischemic stroke serve as the source population for the study and will be identified as inpatients at participating centers.

Inclusion criteria

  • Ischemic stroke according to the American Heart Association (AHA) definition and either:

    1. CT or MRI showing ischemic stroke in the anterior circulation (frontal, parietal or superior temporal lobes), or
    2. Occlusion of the internal carotid, middle cerebral or anterior cerebral arteries on computed tomography angiography (CTA) or magnetic resonance angiography (MRA)

      Onset of ischemic stroke within 48 hours and able to get baseline pMRI within 72 hours of arrival

      4) NIH Stroke Scale ≥ 4 at time of enrollment

Exclusion criteria

Exclusion Criteria:

  • Pre-morbid mRS ≥3
  • Predicted hospital system admission \<72 hours
  • Pacemaker or other MRI contraindications per American College of Radiology guidelines
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute Ischemic Stroke

    Blood pressure variability will be measured in the patients with acute ischemic stroke.

05

What researchers measure

Primary outcomes

  1. Change in Functional outcome

    Modified Rankin Scale, the scale uses a range of 0-6 where higher scores indicate decreased function.

    Time frame: 90 days and 1 Year

  2. Imaging outcome

    Final infarct volume on MRI at 72 hours

    Time frame: 72 hours +/- 60 hours

Secondary outcomes

  1. Incidence of stroke

    Incidence of new (recurrent) ischemic stroke

    Time frame: 90 days

  2. Incidence of stroke

    Incidence of new (recurrent) ischemic stroke

    Time frame: 1 year

  3. Change in Montreal Cognitive Assessment scale (MoCA-BLIND) to assess post-stroke cognition

    Post-stroke cognition will be assessed using the MoCA-BLIND, The MoCA-BLIND assess six different cognitive domains (excludes visual stimulus) over the phone: memory, attention, language, abstraction, delayed recall, and orientation. The MoCA-BLIND is scored from 0-22. Lower scores indicate less cognitive impairment.

    Time frame: 3 days and 1 year

  4. Change in Oral Trails A and B Test to assess post-stroke cognition

    Post-stroke cognition will be assessed using the Oral Trails A and B Test to measure psychomotor speed, visual search, and attention. The test is scored based on how many seconds it takes to complete each part. Higher scores indicate a higher degree of cognitive impairment.

    Time frame: 3 days and 1 year

  5. Change in Category Fluency tests to assess post-stroke cognition

    Categorical verbal fluency tests (CFT) are used to assess the integrity of semantic memory in individuals with brain damage. Participants are given 1 min to produce as many unique words as possible within a semantic category (category fluency) or starting with a given letter (letter fluency). The participant's score in each task is the number of unique correct words.

    Time frame: 3 days and 1 year

  6. Change in Patient Health Questionnaire (PHQ-9) to assess mood

    Nine items asking about the frequency of specific depressive symptoms experienced. The response options are scored from 0 to 3, indicating "not at all" to "nearly every day." The total score on the PHQ-9 ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms. The scoring can also be divided into categories, with scores of 0-4 indicating minimal or no depression, 5-9 indicating mild depression, 10-14 indicating moderate depression, 15-19 indicating moderately severe depression, and 20-27 indicating severe depression.

    Time frame: 3 days and 1 year

  7. Change in General Anxiety Disorder-7 (GAD-7) to assess mood

    General Anxiety Disorder- 7 (GAD-7) is a 7 item self report instrument that measures anxiety Items are scored on a 4-point scale, ranging from "not at all (0)" to "nearly everyday (3)". Item scores are summed with a total score ranging from 0 to 21: 0-4 Minimal anxiety; 5-9 Mild anxiety; 10-14 Moderate anxiety; 15-21 Severe anxiety.

    Time frame: 3 days and 1 year

  8. Change in Lawton Instrumental Activities of Daily Living (IADL) Scale to assess adaptive functioning

    The IADL assesses a person's ability to perform tasks such as using a telephone, doing laundry, and handling finances. It consists of 8 items and total score is achieve by summing all items. Each item is scored 0 = less able or 1 = more able. Total score range is from 0 (low function, dependent) to 8 (high function, independent) for women and 0 through 5 for men to avoid potential gender bias. The higher the score, the greater the person's abilities.

    Time frame: 3 days and 1 year

  9. Change in Katz Index of Independence in Activities of Daily Living (ADL) to assess adaptive functioning

    The Katz IADL assesses the patient's need for assistance in performing basic activities of daily living. Total scores range from 0-12, with higher scores indicating better levels of functioning.

    Time frame: 3 days and 1 year

06

Study locations

3 of 3 sites recruiting
  • Yale-New Haven Hospital
    New Haven, Connecticut 06510, United States
    Recruiting
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    • Shyam Prabhakaran, MD · Contact
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    • W. Taylor Kimberly, MD, PhD · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05756257
Lead sponsor
Yale University
Collaborators
University of Chicago, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Jul 15, 2024
Primary completion
Jul 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Adam de Havenon, MD
Contact
adam.dehavenon@yale.edu
203-785-4085
Adam de Havenon, MD
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion